Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting. Issue 4 (22nd May 2022)

• Record Type: Journal Article
• Authors: Lalive d'Epinay, Murielle; Güsewell, Sabine; Graf, Nicole; Mey, Ulrich J. M.; Driessen, Christoph; Hitz, Felicitas
• Is Part Of: Hematological oncology. Volume 40:Issue 4(2022)
• Page Start: 716
• Page End: 723
• Publication Date: 2022-05-22
• Subjects: elderly -- multiple myeloma -- novel agents; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.3024
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Major improvements in outcome of older patients with multiple myeloma (MM) have been achieved with the introduction of novel agents. Their impact in real‐life treatment of older patients is unclear. In this single center retrospective study, we analyzed the outcome of patients >65 years treated with first‐generation (FGNA) and second‐generation novel agents (SGNA) within two time periods 2012–2014 and 2015–2017. Patients were analyzed based on age, Charlson Comorbidity Index (CCI), International Staging System stage, year of diagnosis and withdrawal of agents due to toxicities. Overall 96 patients were included for analysis. Median age was 73 years (range 65–90), 55 (57%) patients were 65–75 years and 41 (43%) were >75 years old. 84 patients received a first‐line therapy, whereas 45 patients had ≥2 lines of systemic therapy. 20 patients were consolidated with autologous stem cell transplantation. 12 patients had no systemic therapy at all. In 17 of 21 cases a FGNA and in 4 of 21 a SGNA was withdrawn due to toxicity. Median overall survival (OS) for all patients with systemic therapy was 4.75 years (95% CI, 3.05‐NA). Borderline significant improvement of OS was observed in patients diagnosed 2015–2017 compared to 2012–2014 with HR 0.57 (95% CI, 0.31–1.02) p = 0.06. OS significantly differed for comorbid patients with low and intermediate risk CCI, HR 1.94 (95% CI, 1.07–3.54), p = 0.03 in the overall population. OS in patients treated with SGNA was not significantly different in patients with intermediate versus low risk CCI (HR 1.48 (95% CI 0.43–5.14, p = 0.54)). In conclusion, we found a trend toward improved survival for older MM patients after the introduction of novel agents during the observed time period. In patients treated with SGNA a smaller effect that comorbidity negatively affects survival was observed.